Clavis Pharma logo
Company
Technology
Products
Licensing/Partners
Investors
News & Events
Contact us

Welcome to Clavis Pharma

The Key to Superior Pharmaceuticals


Clavis Pharma™ develops new and superior pharmaceuticals by leveraging the potential of its Lipid Vector Technology (LVT). The Company’s objective is to build an attractive pipeline of new drug candidates in oncology and subsequently license these out to strategic partners for further co-development and marketing. Revenues will be generated already at the time of partnering and onwards from up-front payments milestone payments and royalties from licensees.

News & events
Oslo, Norway, August 22, 2008

Clinical development of ELACYT in haematology expanded

Clavis Pharma presents today results for the second quarter and first half-year 2008, and reports an expansion of the ELACYT™ clinical programme in haematology during the second quarter. Promising results were demonstrated for the Oral CP-4126 programme, and a clinical phase I study in cancer patients will be started later this year. In addition, the Intravenous CP-4126 program has progressed towards start of clinical Phase II studies.

Oslo, Norway, July 29, 2008

ELACYT™ Clinical Update

Clavis Pharma (OSE: CLAVIS) announced today that it is amending its clinical program for ELACYT following an evaluation of all clinical data available for ELACYT™, both in haematology and solid tumours.

Oslo, Norway, June 25, 2008

Promising Results for Oral CP-4126

Clavis Pharma announced today that pre-clinical studies have demonstrated that Oral CP-4126 acts as a very efficient pro-drug for gemcitabine (Gemzar®). 

News archive


Search

Subscribe to our newsletter


Learn more about:

  • Annual Report 2007.pdf
  • Clavis Pharma Fact Sheet.pdf

Clavis Pharma ASA

Head Office:
Parkveien 53 B,
NO-0256 Oslo,
Norway

Tel: +47 24110950
Fax: +47 24110951
mail@clavispharma.com